Immunotherapy agent can disrupt viral reservoir in SIV-infected monkeys

February 25, 2016, Emory University
Immunotherapy agent can disrupt viral reservoir in SIV-infected monkeys

An immune-enhancing treatment can push SIV (simian immunodeficiency virus) out of its hideouts in infected monkeys that have the virus controlled with drugs, scientists at Yerkes National Primate Research Center, Emory University report.

The results were presented on Wednesday, February 24 at the Conference on Retroviruses and Opportunistic Infections in Boston by graduate student Geetha Mylvaganam.

Rama Rao Amara, PhD, professor of microbiology and immunology at Yerkes and the Emory Vaccine Center, led the project. Collaborators include Rafi Ahmed, PhD, director of Emory Vaccine Center and a Georgia Research Alliance Eminent Scholar, and Gordon Freeman, PhD, of Dana-Farber Cancer Institute. Mylvaganam is part of the Immunology and Molecular Pathogenesis graduate program at Emory.

Antiretroviral drugs can usually control HIV in chronically infected people, but they can't completely eliminate it. That's because some immune cells harboring the virus remain dormant. A strategy has emerged called "shock and kill" or "kick and kill", aimed at activating those cells, so that the virus can be flushed out.

The Yerkes team tested the effects of blocking PD-1, a molecule that inhibits the immune response during chronic infections, in combination with antiretroviral therapy. Antibodies that block PD-1 have also been tested, with some success, as cancer immunotherapy agents. The team developed a "primatized" anti-PD-1 antibody, to reduce monkeys' immune responses to the antibody itself and enable repeated infusions.

With some SIV-infected monkeys, the researchers treated them with anti-PD-1 antibody for 14 days, starting from 10 days before antiretroviral therapy began. In this situation, the anti-PD-1-treated animals showed more rapid viral suppression (average 42 days in the PD-1 group versus 140 days in controls) and more active antiviral T cells.

In addition, other SIV-infected monkeys were treated with anti-PD-1 antibody (three infusions, with a month between each) after had brought viral levels to a very low level. This resulted in transient reappearances of SIV in their blood, not seen in control animals.

The researchers conclude:

"These results reveal for the first time the potential of PD-1 blockade, both on restoring anti-viral CD8 T cell function, and possibly destabilizing the viral reservoir under ART. They highlight the potential of PD-1 blockade to work synergistically with other therapeutic agents such as vaccines and latency reversing agents to effectively diminish HIV reservoir under ART as a means to establish a functional cure."

Explore further: Scientists discover effects of PD-1 blockade on ART therapy in SIV-infected monkeys

Related Stories

Scientists discover effects of PD-1 blockade on ART therapy in SIV-infected monkeys

March 8, 2012
Scientists have discovered that blocking PD-1 (programmed death-1), an immune molecule that inhibits the immune response to viral infections, can have a significant effect on HIV-like illness in nonhuman primates.

IL-21 repairs immune function in primate model of HIV infection

November 9, 2015
Antiretroviral drugs can suppress HIV for years, but a residual inflammatory imbalance contributes to health problems in infected individuals who are infected with the virus. A novel combination treatment aimed at repairing ...

Overcoming immune exhaustion from chronic HIV infection

December 3, 2015
Chronic HIV infection results in exhaustion of the immune system, a phenomenon characterized by dysfunctional HIV-specific killer T cells. The exhausted T cells display inhibitory proteins on their surface, and scientists ...

SIV shrugs off antibodies in vaccinated monkeys

August 11, 2015
New research on monkeys vaccinated against HIV's relative SIV calls into question an idea that has driven AIDS vaccine work for years. The assumption: a protective vaccine only needs to stimulate moderate levels of antibodies ...

Immune cells proposed as HIV hideout don't last in primate model

October 31, 2014
Where does HIV hide? Antiretroviral drugs can usually control the virus, but can't completely eliminate it. So any strategy to eradicate HIV from the body has to take into account not only the main group of immune cells the ...

HIV antibody infusion safely suppresses virus in infected people

December 23, 2015
A single infusion of a powerful antibody called VRC01 can suppress the level of HIV in the blood of infected people who are not taking antiretroviral therapy (ART), scientists at the National Institutes of Health report in ...

Recommended for you

HIV-1 viruses transmitted at birth are resistant to antibodies in mother's blood

April 19, 2018
Of the genetically diverse population of HIV-1 viruses present in an infected pregnant woman, the few she might transmit to her child during delivery are resistant to attack by antibodies in her blood, according to new research ...

Top HIV cure research team refutes major recent results on how to identify HIV persistence

April 18, 2018
An international team focused on HIV cure research spearheaded by The Wistar Institute in collaboration with the University of Pennsylvania and Vall d'Hebron Research Institute (VHIR) in Barcelona, Spain, established that ...

Scientists discover new way that HIV evades the immune system

April 17, 2018
Scientists have just discovered a new mechanism by which HIV evades the immune system, and which shows precisely how the virus avoids elimination. The new research shows that HIV targets and disables a pathway involving a ...

Team develops new way to fight HIV transmission

April 16, 2018
Scientists at the University of Waterloo have developed a new tool to protect women from HIV infection.

Genetically altered broadly neutralizing antibodies protect monkeys from HIV-like virus

April 16, 2018
Two genetically modified broadly neutralizing antibodies (bNAbs) protected rhesus macaques from an HIV-like virus, report scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National ...

How does HIV escape cellular booby traps?

April 5, 2018
HIV is believed to have evolved from a simian immunodeficiency virus, or SIV, that originated in chimpanzees. How SIV made the species jump has remained a mystery, since humans possess a defense mechanism that should prevent ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.